AMRX vs. AMPH, DCPH, RCKT, NAMS, ARDX, GLPG, SNDX, KROS, EWTX, and AGIO
Should you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include Amphastar Pharmaceuticals (AMPH), Deciphera Pharmaceuticals (DCPH), Rocket Pharmaceuticals (RCKT), NewAmsterdam Pharma (NAMS), Ardelyx (ARDX), Galapagos (GLPG), Syndax Pharmaceuticals (SNDX), Keros Therapeutics (KROS), Edgewise Therapeutics (EWTX), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical preparations" industry.
Amphastar Pharmaceuticals (NASDAQ:AMPH) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership and community ranking.
In the previous week, Amphastar Pharmaceuticals had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 19 mentions for Amphastar Pharmaceuticals and 16 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.91 beat Amphastar Pharmaceuticals' score of 0.50 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.
Amphastar Pharmaceuticals has higher earnings, but lower revenue than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amphastar Pharmaceuticals has a net margin of 21.34% compared to Amphastar Pharmaceuticals' net margin of -6.76%. Amphastar Pharmaceuticals' return on equity of 234.06% beat Amneal Pharmaceuticals' return on equity.
Amphastar Pharmaceuticals has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.
65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Amphastar Pharmaceuticals currently has a consensus target price of $66.00, suggesting a potential upside of 56.36%. Amneal Pharmaceuticals has a consensus target price of $8.25, suggesting a potential upside of 23.87%. Given Amneal Pharmaceuticals' higher possible upside, research analysts plainly believe Amphastar Pharmaceuticals is more favorable than Amneal Pharmaceuticals.
Amphastar Pharmaceuticals received 376 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Amneal Pharmaceuticals an outperform vote while only 66.72% of users gave Amphastar Pharmaceuticals an outperform vote.
Summary
Amphastar Pharmaceuticals beats Amneal Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Amneal Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amneal Pharmaceuticals Competitors List
Related Companies and Tools
